Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| 2012-001144-22 | EudraCT Number |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This randomized, open-label study will evaluate the efficacy and safety of neoadjuvant bevacizumab in participants with initially unresectable, FIGO stage IIIC/IV ovarian, tubal, or peritoneal cancer. Participants will be randomized to receive 8 cycles of carboplatin plus paclitaxel with or without bevacizumab before surgery (interval debulking surgery [IDS]). Surgery will be scheduled 28 days after the last course of neoadjuvant treatment in participants with resectable cancer. Participants with unresectable cancer will go through the follow-up period. All participants will receive bevacizumab for Cycles 6 to 26.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Carboplatin + Paclitaxel + Bevacizumab | Experimental | Participants will receive 4 cycles of neoadjuvant therapy prior to IDS and 22 cycles of adjuvant therapy before entering long-term follow-up. Each cycle will be 3 weeks in length. Carboplatin and paclitaxel will be administered during Cycles 1 to 8. Bevacizumab will be administered during both the neoadjuvant and the adjuvant treatment periods in Cycles 1 to 26 (no treatment in Cycles 4 and 5). |
|
| Carboplatin + Paclitaxel | Active Comparator | Participants will receive 4 cycles of neoadjuvant therapy prior to IDS and 22 cycles of adjuvant therapy before entering long-term follow-up. Each cycle will be 3 weeks in length. Carboplatin and paclitaxel will be administered during Cycles 1 to 8. Bevacizumab will be administered only during the adjuvant treatment period in Cycles 6 to 26. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Carboplatin | Drug | Carboplatin will be administered at a dose calculated according to the Calvert formula ([participant's glomerular filtration rate + 25] multiplied by the target area under the concentration-time curve [AUC] of 5 milligrams per milliliter per minute [mg/mL/min]), as intravenous [IV] infusion over 30-60 minutes [min] every 3 weeks). |
| Measure | Description | Time Frame |
|---|---|---|
| Percentage of Participants with Complete Resection After IDS | After IDS (approximately 4 months from randomization) | |
| Percentage of Participants with Different CC Scores After IDS | After IDS (approximately 4 months from randomization) |
| Measure | Description | Time Frame |
|---|---|---|
| Percentage of Participants with Objective Response According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) | At IDS (approximately 3 months); at Cycle 26 (approximately 22 months); and at last tumor assessment (up to approximately 38 months) | |
| Percentage of Participants with Response According to Cancer Antigen (CA)-125 Levels |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Clinical Trials | Hoffmann-La Roche | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Chu D'Amiens | Amiens | 80054 | France | |||
| HOPITAL JEAN MINJOZ; Oncologie |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 37185961 | Derived | Gaitskell K, Rogozinska E, Platt S, Chen Y, Abd El Aziz M, Tattersall A, Morrison J. Angiogenesis inhibitors for the treatment of epithelial ovarian cancer. Cochrane Database Syst Rev. 2023 Apr 18;4(4):CD007930. doi: 10.1002/14651858.CD007930.pub3. |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
| Paclitaxel | Drug | Paclitaxel will be administered at a dose of 175 milligrams per meter-squared [mg/m^2] as IV infusion over 3 hours using a rate controlling device every 3 weeks, or at a dose of 80 mg/m^2 as IV infusion over 1 hour using a rate controlling device every week (only during Cycles 5 to 8). |
|
| Bevacizumab | Drug | Bevacizumab will be administered at a dose of 15 milligrams per kilogram [mg/kg] as IV infusion over 30-90 min every 3 weeks. |
|
|
| At IDS (approximately 3 months); at Cycle 26 (approximately 22 months); and at last CA-125 assessment (up to approximately 38 months) |
| Percentage of Participants with RECIST v1.1 Objective Response and CA-125 Response | At Cycle 26 (approximately 22 months) and at last response assessment (up to approximately 38 months) |
| Percentage of Participants with RECIST v1.1 Objective Response Without CA-125 Response | At Cycle 26 (approximately 22 months) and at last response assessment (up to approximately 38 months) |
| Percentage of Participants with CA-125 Response Without RECIST v1.1 Objective Response | At Cycle 26 (approximately 22 months) and at last response assessment (up to approximately 38 months) |
| Number of Participants with Disease Progression or Death From any Cause | From Baseline to disease progression or death due to any cause (up to approximately 38 months) |
| Progression-Free Survival (PFS) According to RECIST v1.1 | From Baseline to disease progression or death due to any cause (up to approximately 38 months) |
| Percentage of Participants with Serious Adverse Events (SAEs) and Non-SAEs | SAEs: from randomization up to last assessment (up to approximately 38 months); non-SAEs: from Day 1 up to 28 days after last dose (up to approximately 23 months) |
| Besançon |
| 25030 |
| France |
| Institut Bergonie; Oncologie | Bordeaux | 33076 | France |
| Centre Francois Baclesse; Chir Gynecologique | Caen | 14076 | France |
| Centre Jean Perrin; Chir Generale Oncologie | Clermont-Ferrand | 63011 | France |
| Centre Oscar Lambret; Cancerologie Gynecologique | Lille | 59020 | France |
| Institut J Paoli I Calmettes; Chir II | Marseille | 13273 | France |
| Centre Val Aurelle Paul Lamarque; Chir A1 | Montpellier | 34298 | France |
| Centre Antoine Lacassagne; Hopital De Jour A2 | Nice | 06189 | France |
| Institut Curie; Chir Generale Gyneco Oncologique | Paris | 75231 | France |
| Hop Europeen Georges Pompidou; Gynecologie | Paris | 75908 | France |
| HOPITAL TENON; Cancerologie Medicale | Paris | 75970 | France |
| Centre Rene Huguenin; Chir Generale Oncologique | Saint-Cloud | 92210 | France |
| Hopital Rangueil; CHIR Generale Et Gynecologique | Toulouse | 31059 | France |
| Institut Gustave Roussy; Departement Chirurgie Generale /Unite Tarn | Villejuif | 94805 | France |
| ID | Term |
|---|---|
| D010051 | Ovarian Neoplasms |
| ID | Term |
|---|---|
| D004701 | Endocrine Gland Neoplasms |
| D009371 | Neoplasms by Site |
| D009369 | Neoplasms |
| D010049 | Ovarian Diseases |
| D000291 | Adnexal Diseases |
| D005831 | Genital Diseases, Female |
| D052776 | Female Urogenital Diseases |
| D005261 | Female Urogenital Diseases and Pregnancy Complications |
| D000091642 | Urogenital Diseases |
| D005833 | Genital Neoplasms, Female |
| D014565 | Urogenital Neoplasms |
| D000091662 | Genital Diseases |
| D004700 | Endocrine System Diseases |
| D006058 | Gonadal Disorders |
Not provided
Not provided
| ID | Term |
|---|---|
| D016190 | Carboplatin |
| D017239 | Paclitaxel |
| D000068258 | Bevacizumab |
| ID | Term |
|---|---|
| D056831 | Coordination Complexes |
| D009930 | Organic Chemicals |
| D043823 | Taxoids |
| D043822 | Cyclodecanes |
| D003516 | Cycloparaffins |
| D006840 | Hydrocarbons, Alicyclic |
| D006844 | Hydrocarbons, Cyclic |
| D006838 | Hydrocarbons |
| D004224 | Diterpenes |
| D013729 | Terpenes |
| D061067 | Antibodies, Monoclonal, Humanized |
| D000911 | Antibodies, Monoclonal |
| D000906 | Antibodies |
| D007136 | Immunoglobulins |
| D007162 | Immunoproteins |
| D001798 | Blood Proteins |
| D011506 | Proteins |
| D000602 | Amino Acids, Peptides, and Proteins |
| D012712 | Serum Globulins |
| D005916 | Globulins |
Not provided
Not provided